COPT Defense Properties $CDP Shares Sold by Lasalle Investment Management Securities LLC

Lasalle Investment Management Securities LLC cut its stake in shares of COPT Defense Properties (NYSE:CDP) by 58.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 185,258 shares of the company’s stock after selling 255,379 shares during the quarter. Lasalle Investment Management Securities LLC’s holdings in COPT Defense Properties were worth $5,150,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of CDP. Royal Bank of Canada lifted its holdings in shares of COPT Defense Properties by 12.1% during the first quarter. Royal Bank of Canada now owns 104,602 shares of the company’s stock worth $2,853,000 after purchasing an additional 11,316 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of COPT Defense Properties by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 67,030 shares of the company’s stock worth $1,828,000 after purchasing an additional 2,931 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of COPT Defense Properties by 5.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 834,042 shares of the company’s stock worth $22,744,000 after purchasing an additional 39,683 shares during the period. Jane Street Group LLC lifted its holdings in shares of COPT Defense Properties by 152.4% during the first quarter. Jane Street Group LLC now owns 214,122 shares of the company’s stock worth $5,839,000 after purchasing an additional 129,303 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of COPT Defense Properties by 11.8% during the second quarter. Invesco Ltd. now owns 758,513 shares of the company’s stock worth $20,920,000 after purchasing an additional 80,153 shares during the period.

Insider Buying and Selling at COPT Defense Properties

In other news, Director Robert L. Denton sold 3,922 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $32.38, for a total value of $126,994.36. Following the completion of the transaction, the director owned 3,803 shares in the company, valued at $123,141.14. This trade represents a 50.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.66% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CDP has been the subject of a number of recent analyst reports. Weiss Ratings raised COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, April 21st. Evercore reissued an “outperform” rating and issued a $38.00 target price on shares of COPT Defense Properties in a report on Tuesday, April 28th. JPMorgan Chase & Co. raised their target price on COPT Defense Properties from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 15th. Truist Financial raised their target price on COPT Defense Properties from $31.00 to $33.00 and gave the company a “hold” rating in a report on Tuesday, March 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $37.00 target price on shares of COPT Defense Properties in a report on Wednesday, April 29th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

COPT Defense Properties Price Performance

COPT Defense Properties stock opened at $32.05 on Monday. COPT Defense Properties has a one year low of $26.91 and a one year high of $33.33. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85. The business has a fifty day moving average of $31.74 and a two-hundred day moving average of $30.82. The company has a market cap of $3.63 billion, a P/E ratio of 23.22 and a beta of 0.79.

COPT Defense Properties (NYSE:CDP) last released its earnings results on Monday, April 27th. The company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.34). COPT Defense Properties had a net margin of 20.10% and a return on equity of 10.02%. The business had revenue of $200.64 million during the quarter, compared to analyst estimates of $185.10 million. During the same period last year, the business posted $0.65 EPS. COPT Defense Properties’s revenue was up 6.8% compared to the same quarter last year. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. As a group, analysts predict that COPT Defense Properties will post 2.78 earnings per share for the current fiscal year.

COPT Defense Properties Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be given a $0.32 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 4.0%. COPT Defense Properties’s dividend payout ratio (DPR) is currently 92.75%.

About COPT Defense Properties

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.